Details for Patent: 9,474,754
✉ Email this page to a colleague
Which drugs does patent 9,474,754 protect, and when does it expire?
Patent 9,474,754 protects BRAFTOVI and is included in one NDA.
This patent has fifty patent family members in thirty-eight countries.
Summary for Patent: 9,474,754
| Title: | Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-.alpha. inhibitor |
| Abstract: | A pharmaceutical combination comprising (a) a B-Raf inhibitor, (b) a EGFR inhibitor and, optionally, (c) a PI3K inhibitor; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination. |
| Inventor(s): | Caponigro; Giordano (Foxborough, MA), Stuart; Darrin (Pleasant Hill, CA), Moutouh-De Parseval; Laure (Basel, CH) |
| Assignee: | NOVARTIS AG (Basel, CH) |
| Application Number: | 14/419,256 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Compound; Delivery; |
Drugs Protected by US Patent 9,474,754
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,474,754
| PCT Information | |||
| PCT Filed | August 05, 2013 | PCT Application Number: | PCT/US2013/053619 |
| PCT Publication Date: | February 13, 2014 | PCT Publication Number: | WO2014/025688 |
International Family Members for US Patent 9,474,754
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 092045 | ⤷ Sign Up | |||
| Australia | 2013299841 | ⤷ Sign Up | |||
| Brazil | 112015002384 | ⤷ Sign Up | |||
| Canada | 2879548 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
